Ziqin Wang | Toxicology and Pharmaceutical Science | Innovative Research Award

Innovative Research Award

Ziqin Wang
Beijing Chaoyang Kaiwen Academy

Researcher Profile
Affiliation Beijing Chaoyang Kaiwen Academy
Country China
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0009-0004-2036-3316

Ziqin Wang is associated with Beijing Chaoyang Kaiwen Academy in China, with toxicology and pharmaceutical science identified as the relevant subject areas in the supplied profile. These disciplines investigate the biological effects of chemical substances, pharmaceutical safety, therapeutic development, and evidence-based approaches to evaluating medicines.methodological quality, and research relevance. Specific publications, research achievements, and bibliometric indicators require independent verification before attribution. Established toxicological assessment principles and pharmaceutical research guidance provide a foundation for evaluating scientific contributions in these fields.[1][2]

Abstract

This article presents an academic recognition profile for Ziqin Wang of Beijing Chaoyang Kaiwen Academy, China, in connection with the Innovative Research Award and the International Invention Awards. The stated subject areas are toxicology and pharmaceutical science, which encompass chemical safety, biological responses, therapeutic substances, and pharmaceutical development. The profile outlines relevant research themes and describes considerations for evaluating originality, methodological quality, scientific integrity, and practical relevance. Specific publications, research achievements, citation counts, and other bibliometric indicators have not been independently verified. Authoritative institutional records and scholarly databases should be consulted before attributing individual accomplishments or drawing conclusions about research impact or award eligibility.

Keywords

Ziqin Wang, Innovative Research Award, International Invention Awards, toxicology, pharmaceutical science, drug safety, pharmacological research, chemical risk assessment, pharmaceutical innovation, scientific research, biomedical development, research evaluation.

Introduction

Scientific innovation advances knowledge by introducing new methods, testing hypotheses, and addressing unresolved research questions. Toxicology and pharmaceutical science contribute to this process through investigations of chemical hazards, biological mechanisms, drug safety, and therapeutic development. Evaluating work in these areas requires attention to experimental design, reproducibility, ethical conduct, and the strength of supporting evidence. Internationally recognized scientific and pharmaceutical guidance provides useful context for understanding these requirements.[1][2]

Research Profile

The supplied information identifies Ziqin Wang with Beijing Chaoyang Kaiwen Academy in China and lists toxicology and pharmaceutical science as relevant subject areas. These fields combine concepts from chemistry, biology, pharmacology, and health sciences to examine the effects of substances and the development of therapeutic products. The available information does not independently establish a specific research appointment, degree, laboratory affiliation, or publication history. Additional details should be confirmed through institutional documentation, scholarly records, or the researcher’s verified public profile before inclusion in a formal academic biography.[3]

Research Contributions

Potential contributions within toxicology and pharmaceutical science include the assessment of chemical hazards, analysis of dose-response relationships, investigation of biological mechanisms, and development of improved methods for evaluating substance safety. Pharmaceutical research can also address formulation, drug delivery, analytical techniques, and the evaluation of therapeutic candidates. These examples describe the broader scientific disciplines and should not be interpreted as confirmed achievements by Ziqin Wang. Individual discoveries, inventions, experimental results, or original methods should be attributed only when supported by identifiable publications, patents, institutional records, or other reliable evidence.[1][2]

Publications

A verified publication record helps establish research activity, subject expertise, and scholarly contributions. Relevant materials may include peer-reviewed journal articles, conference papers, research reports, and publications describing original experimental findings. Each record should be checked for authorship, publication details, journal information, and a persistent identifier such as a digital object identifier (DOI), when available. No specific publication or DOI has been verified for this profile. Consequently, publication titles and numerical research indicators should be added only after checking appropriate scholarly databases and original publication records.[3]

Research Impact

Research impact can be examined through scientific quality, reproducibility, independent citation, practical application, and relevance to important research questions. In toxicology and pharmaceutical science, meaningful outcomes may include stronger safety assessment methods, improved understanding of biological effects, or evidence that supports further therapeutic development. Citation counts and h-index values can indicate aspects of scholarly visibility but cannot independently establish originality or practical benefit. An evidence-based assessment of Ziqin Wang’s research impact requires verified publications, documented research outputs, and independent evidence of how the work has contributed to scientific understanding or subsequent applications.[1]

Award Suitability

The Innovative Research Award provides a framework for recognizing work that may demonstrate originality, methodological rigor, scientific relevance, and responsible innovation. In toxicology and pharmaceutical science, a nomination may be supported by documented research findings, validated methods, relevant publications, patents, or evidence of practical application. The supplied profile information alone is insufficient to establish award eligibility or determine the strength of a nomination. A fair assessment should use the International Invention Awards’ applicable eligibility requirements and evaluation criteria, supported by reliable documentation and a transparent review process.[3]

Conclusion

This profile presents Ziqin Wang in the context of Beijing Chaoyang Kaiwen Academy, China, and the subject areas of toxicology and pharmaceutical science. It outlines the broader scientific context of the Innovative Research Award and the importance of originality, reproducibility, and evidence-based evaluation. A complete academic assessment requires verified scholarly outputs, documented research achievements, and confirmation of the relevant award criteria. The inclusion of numbered references links the discussion to sources on toxicological assessment, pharmaceutical guidance, and researcher identification, while maintaining a clear distinction between supplied profile information and independently established facts.

References

  1. ORCID. (n.d.). ORCID: Connecting Research and Researchers. ORCID.
    https://orcid.org/0009-0004-2036-3316
  2. Journal article. (2026. ) Cardiolipin-Specific Targeting of Melittin via Arg22 in Lipid Membranes: A Natural Toxin-Based Strategy for Treating Mitochondrial Dysfunction in Aging and Disease.
    https://doi.org/10.3390/toxins18100432
  3. International Invention Awards. (2026.). Official website.
    https://inventionawards.org/

Stephen Chelko | Toxicology and Pharmaceutical Science | Innovative Research Award

Innovative Research Award

Stephen Chelko
Florida State University College of Medicine

Stephen Chelko
Affiliation Florida State University College of Medicine
Country United States
Scopus ID 54973874200
Documents 47
Citations 1,649
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0003-1675-5945

Stephen Chelko is a researcher affiliated with the Florida State University College of Medicine whose documented scholarly profile is associated with toxicology and pharmaceutical science. Available bibliometric information records 47 documents, 1,649 citations, and an h-index of 18, providing a quantitative basis for assessing research visibility and scholarly influence. [1]

Abstract

Stephen Chelko is a researcher associated with Florida State University College of Medicine and the fields of toxicology and pharmaceutical science. His indexed scholarly record comprises 47 documents, 1,649 citations, and an h-index of 18, according to the supplied Scopus profile information. These indicators provide a measurable basis for describing his research visibility and citation impact within scholarly databases. His profile may be considered in the context of recognition for innovative research, particularly where scientific investigation, translational relevance, and contribution to biomedical knowledge are central criteria. The Innovative Research Award provides a framework for highlighting documented scholarly achievement and research significance.

Keywords

Stephen Chelko; Innovative Research Award; toxicology; pharmaceutical science; biomedical research; Florida State University College of Medicine; research impact; scholarly publications; citation analysis; translational science.

Introduction

Academic recognition commonly considers the quality, relevance, originality, and influence of a researcher’s scholarly work. In this context, Stephen Chelko’s documented profile combines research activity in toxicology and pharmaceutical science with measurable bibliometric indicators. The available Scopus record identifies 47 documents, 1,649 citations, and an h-index of 18. [1]

Research Profile

Chelko’s stated subject area is Toxicology and Pharmaceutical Science, positioning his scholarly profile within disciplines concerned with biological effects, therapeutic development, pharmaceutical research, and related biomedical questions. His affiliation with Florida State University College of Medicine further places this work within an academic medical environment. [4]

Research Contributions

The available information supports describing Chelko’s contribution through his documented publication record and citation footprint rather than assigning unsupported claims about individual discoveries. Forty-seven indexed documents indicate sustained scholarly output, while the recorded citation count suggests that his published research has been referenced by subsequent academic literature. [1]

Publications

The supplied researcher profile reports 47 documents indexed in Scopus. Because complete publication titles, journals, publication years, and article-level DOI information were not supplied, this page does not attribute individual papers or DOI records without verification. The Scopus author profile provides the appropriate source for reviewing the complete indexed publication record. [1]

Research Impact

Research impact can be assessed through several complementary dimensions, including scholarly citations, publication continuity, disciplinary relevance, and potential contribution to scientific practice. Chelko’s reported 1,649 citations and h-index of 18 provide quantitative indicators of scholarly visibility, although bibliometric measures should be interpreted alongside qualitative assessment of research originality and significance. [1]

Award Suitability

The documented research profile is relevant to an Innovative Research Award because it demonstrates sustained scholarly activity in a biomedical subject area and a measurable citation record. Final award suitability should nevertheless depend on the official nomination criteria, verified publications, originality of contributions, supporting evidence, and independent evaluation by the responsible award committee. [5]

Conclusion

Stephen Chelko’s supplied academic profile presents a researcher working in toxicology and pharmaceutical science, affiliated with Florida State University College of Medicine. The reported record of 47 documents, 1,649 citations, and an h-index of 18 provides a measurable foundation for academic recognition. These indicators should be considered together with verified research quality and innovation.

References

  1. Elsevier. (n.d.). Scopus author details: Stephen Chelko, Author ID 54973874200. Scopus.
    https://www.scopus.com/pages/authors/54973874200
  2. ORCID. (n.d.). Stephen Chelko, ORCID iD 0000-0003-1675-5945. ORCID.
    https://orcid.org/0000-0003-1675-5945
  3. Google Scholar. (n.d.). Stephen Chelko — Google Scholar profile.
    https://scholar.google.com/citations?hl=en&user=5Hq6SM0AAAAJ
  4. Journal article. (2019.). Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy.
    https://doi.org/10.1161/CIRCULATIONAHA.119.040676
  5. International Invention Awards. (2026.). Official Award Information.
    https://inventionawards.org/

Lee Jia | Pharmacy | Research Excellence Award

Prof. Lee Jia | Pharmacy | Research Excellence Award

Distinguished Professor and Director in Henan University, United States

Prof. Lee Jia is a highly accomplished pharmacologist with a strong academic foundation, earning his Ph.D. in Pharmacology from the State University of New York under Nobel Laureate Robert F. Furchgott and completing postdoctoral research at Duke University Medical Center in Durham, North Carolina. He currently serves as Distinguished Professor at The First Affiliated Hospital of Henan University and has held key leadership roles including Director of the Marine Drug R&D Center at Minjiang University and founding director of a cancer metastasis research center at Fuzhou University. His international career includes senior scientific positions at the National Cancer Institute, National Institutes of Health, and collaborations with institutions such as University of Geneva and Technological University Dublin. He is widely recognized for contributions to pharmacology, toxicology, nanomedicine, and cancer research, earning distinctions such as Fellow of the American Association of Pharmaceutical Scientists, Fellow of the Academy of Toxicological Sciences, and selection among the world’s top 2% scientists by Stanford University and Elsevier. He has received numerous prestigious honors including major national innovation awards in China, international research recognitions, and leadership roles in scientific societies such as the Chinese Pharmaceutical Association. In addition to his research impact, he has made extensive contributions as an editor, reviewer, and scientific organizer across leading journals and global conferences, shaping advancements in drug discovery and translational medicine.

Citation Metrics (Scopus)

15000
12000
9000
6000
3000
100
0

Citations
13224

Documents
226

h-index
55

Citations

Documents

h-index

View Scopus Profile

Featured Publications

 

Jiankang Liu | Pharmacology | Research Excellence Award

After Completing the Registration Process, your Biography will be displayed here.

Register by using your Entry ID: 26048

Register Here

 

Dr. Natascia Bruni | Chemistry | Best Researcher Award

Dr. Natascia Bruni | Chemistry | Best Researcher Award

Candioli Pharma srl, Italy.

Natascia Bruni is an experienced regulatory compliance and quality management professional with over two decades of experience in the pharmaceutical and feed supplements industries. Currently, she serves as the Compliance Unit Director, Qualified Person, and QPPV at Acel Pharma srl, where she plays a pivotal role in ensuring regulatory compliance, managing product registrations, and overseeing pharmacovigilance activities. Throughout her career, Natascia has worked across various sectors, including pharmaceutical companies (human and veterinary), focusing on quality assurance, regulatory affairs, and strategic business compliance. She is well-versed in navigating complex regulatory landscapes and has made substantial contributions to corporate governance, legal risk management, and quality audits.

Profile

Scopus

Orcid

Education 🎓

Natascia Bruni's educational background demonstrates her deep expertise in both scientific and management fields, which has greatly contributed to her successful career in regulatory affairs and quality management. She completed her degree in Chemistry (Nuclear) at the University of Turin from 1991 to 1996, earning the highest distinction with a final vote of 110/110 con lode. This solid foundation in chemistry equipped her with a thorough understanding of chemical processes and analytical methods, which would later be pivotal in her regulatory and quality assurance roles in the pharmaceutical industry.

In addition to her scientific education, Natascia pursued specialized training in Regulatory Affairs and Pharmacovigilance for Drugs between 2001 and 2002, sharpening her skills in the complex regulatory frameworks governing drug safety and compliance. This training became essential in her role as a Qualified Person and QPPV in various pharmaceutical companies, where she led efforts to ensure products met both safety and regulatory standards.

Furthermore, Natascia completed a Business Management Course from 2015 to 2018, which enhanced her leadership, strategic planning, and operational management abilities. This course helped her integrate business and regulatory perspectives, allowing her to lead teams and drive organizational success in compliance-related activities.

Natascia also deepened her technical expertise by attending the School in Technology Enhanced Chemical Synthesis from 1996 to 1999, where she learned advanced techniques in chemical synthesis that continue to inform her work in pharmaceutical and feed supplement regulatory processes. Her multi-disciplinary education has provided a strong foundation for her leadership role in compliance and regulatory affairs, combining scientific rigor with strategic management skills.

Experience 💼

Compliance Unit Director - Qualified Person - QPPV (2012–Present), Acel Pharma srl (Candioli Group), Beinasco (Torino)
Responsible for ensuring the regulatory compliance of raw materials and finished products, overseeing registration/approvals, and managing import/export activities. Works closely with various departments to ensure that all products sold comply with national and international regulations.

Quality Unit Manager & Qualified Person (2007–2012), Olon Spa (Fidia Group), Rodano (MI) and Settimo Torinese (To)
Led the harmonization of QA/QC and regulatory procedures across two sites, ensuring GMP and regulatory compliance for the company’s product portfolio. Managed communications with health authorities and conducted quality audits for suppliers.

Chemistry Department Responsible (1997–1999), Antibiotic Spa, Settimo Torinese (To)
Conducted independent research and developed experimental procedures within the research project scope.

Researcher (1996–1997), Antibiotic Spa, Settimo Torinese (To)
Developed analytical methods and processes in the field of pharmaceutical research.

Research Interests 🔬

Regulatory Compliance in Pharmaceutical Products 📜

Natascia is particularly interested in the regulatory compliance of both raw materials and finished products in the pharmaceutical industry. Her work emphasizes the critical importance of navigating complex regulatory frameworks and ensuring that all pharmaceutical products, especially those used in veterinary medicine, comply with the highest standards of food safety, quality control, and marketing.

Pharmacovigilance & Product Registration 💊

A key area of Natascia's research is in pharmacovigilance, particularly focusing on the monitoring and reporting of adverse effects for drugs, ensuring products maintain safety and compliance throughout their lifecycle. She explores the processes involved in product registration, striving to streamline the approvals and regulatory checks necessary for market entry, particularly in international markets.

Process Improvement Methodologies 🔧

Natascia is also keen on exploring process improvement methodologies within the regulatory compliance space. Her work in this area aims to enhance operational efficiency, reduce legal risks, and strengthen internal control structures. By continuously improving regulatory and operational processes, she contributes to creating a safer and more efficient regulatory environment for pharmaceutical companies, particularly in the feed supplement and veterinary drug sectors.

Awards 🏅

University Senate Award: Best Academic Graduate (1996)
Awarded for excellence in academic performance by the Presidency Council of the Italian Chamber.

OPTIME Award: Best Experimental Dissertation of the Year (1996)
Recognized by the Industrial Union for outstanding research work.

Publications 📚

"Molecular Characterization of the Gorgonzola Cheese Mycobiota and Selection of a Putative Probiotic Saccharomyces cerevisiae var. boulardii for Evaluation as a Veterinary Feed Additive" Published in Applied Microbiology, 2024, 4(2), pp. 650–664.

"Efficacy of a Dietary Supplement in Dogs with Osteoarthritis: A Randomized Placebo-Controlled, Double-Blind Clinical Trial"
Published in PLoS ONE, 2022, 17(2), e0263971.

"Chronic Kidney Disease and Dietary Supplementation: Effects on Inflammation and Oxidative Stress", Published in Veterinary Sciences, 2021, 8(11), 277.
"Chronic Intestinal Disorders in Humans and Pets: Current Management and the Potential of Nutraceutical Antioxidants as Alternatives", Published in Animals, 2022, 12(7), 812.